your initial deposit *subject to change and depends on individual circumstances.
Diamedica is a biotechnology company focused on the development of treatments for Type 2 diabetes. The Company's lead candidate, DM-71, is in Phase II clinical studies to determine its effectiveness as compared to a placebo treatment.
Recent Sector News
ImmuPharma has agreed a £50mln equity drawdown facility, one of the biggest deals of its kind in London, to fund the late-stage development of Lupuzor, its breakthrough drug for auto-immune disease lupus. The five-year funding package will be provided by Darwin Strategic, owned by Henderson Global Investors.
ImmuPharma’s £50mln equity funding package agreed with a subsidiary of Henderson Global Investors “mitigates risk” and provides “external validation” for the firm’s plans to take its lead drug into late-stage clinical trials.
The struggle for any ambitious biopharma group is finding sufficient cash to take a breakthrough treatment to the point where it maximises value for the company and its investors. For e-Therapeutics, the funding silver bullet was fired in March when it successfully concluded a £40mln cash call
City broker N+1 Singer has raised its valuation of Oxford Pharmascience by 33% to reflect the potential of its adaptation of a top selling painkiller. Its target price rises to 9.2 pence a share – representing a significant premium to the current share price of 3.92 pence.
Cash rich drug developer e-Therapeutics is gaining momentum with the first findings from its phase I programme of its lead cancer drug, ETS2101, coming through, while its anti-depressant drug, ETS6103, is lined up for a phase IIb trial.
At the Chesterfield Mayfair Hotel, London on Thursday, May 16, we will be showcasing Alliance Pharma (LON:APH), Brightside Group (LON:BRT) and Motive Television (LON:MTV).
Investors interested in Diamedica recently viewed
- iSonea Limited (ASX: ISN) From Wheeze Identification to Wheeze Quantification
- Sphere Medical (AIM: SPHR) Raising the Standard of Critical Care
- Summit plc (AIM: SUMM) .
- Renovo Group Plc (LSE: RNVO) Renovo: Improving scar appearance and enhancing wound healing
- e-Therapeutics plc (AIM: ETX) Systems Biology Drug Discovery